Pharmaceutical combination and use thereof
US-2024189341-A1 · Jun 13, 2024 · US
Live attenuated bordetella strains as a single dose vaccine against whooping cough
US9119804B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9119804-B2 |
| Application number | US-22489507-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 7, 2007 |
| Priority date | Mar 10, 2006 |
| Publication date | Sep 1, 2015 |
| Grant date | Sep 1, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A triple mutated Bordetella strain which is a BPZE1 strain deposited with the Collection Nationale de Culture Microorganismes (C.N.C.M.) on Mar. 9, 2006, under number 1-3585. 2. An immunogenic composition comprising the attenuated mutated Bordetella strain according to claim 1 . 3. The immunogenic composition according to claim 2 , further comprising a pharmaceutically suitable excipient, vehicle and/or carr…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- A61K39/099Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9119804B2 cover?
- A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic compos…
- Who is the assignee on this patent?
- Locht Camille, Mielcarek Nathalie, Debrie Anne-Sophie, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/099. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).